bibliographicCitation |
Liao W, Lei W, Feng M, Yang Y, Wu Q, Zhou K, Bai L, Wen F, Li Q. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States. Adv Ther. 2021 Dec;38(12):5662–70. doi: 10.1007/s12325-021-01926-0. PMID: 34664194. |